Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of NI-0401 in acute cellular renal allograft rejection
2007-001857-24Phase 2Completed
- Sponsor
- Lightchain Bioscience
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of foralumab in Acute cellular kidney allograft rejection, sponsored by Lightchain Bioscience. Primary endpoint: Safety and tolerability of NI-0401. Started May 2007; status: completed.
02
Drugs
foralumab
03
Conditions
Acute cellular kidney allograft rejection
Beyond the preview
Go deeper on 2007-001857-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001857-24.